For research use only. Not for therapeutic Use.
ARD-2051(CAT: I040940) is a potent, orally active androgen receptor (AR) proteolysis-targeting chimera (PROTAC) degrader. It induces selective degradation of AR proteins, achieving DC50 values as low as 0.6 nM in both LNCaP and VCaP prostate cancer cell lines. By targeting AR for degradation, ARD-2051 effectively disrupts androgen signaling, a key driver of prostate cancer progression. This compound shows significant promise in prostate cancer research, offering a new approach for therapeutic intervention in AR-dependent tumors. ARD-2051 is highly relevant for Cancer Disease Research, particularly in the development of targeted therapies for prostate cancer.
| CAS Number | 2632305-17-8 |
| Synonyms | 2-chloro-4-[(3S)-8-[4-[4-[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]azetidin-3-yl]piperazine-1-carbonyl]phenyl]-3-methyl-2,8-diazaspiro[4.5]decan-2-yl]benzonitrile |
| Molecular Formula | C43H45ClN8O5 |
| Purity | ≥95% |
| IUPAC Name | 2-chloro-4-[(3S)-8-[4-[4-[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]azetidin-3-yl]piperazine-1-carbonyl]phenyl]-3-methyl-2,8-diazaspiro[4.5]decan-2-yl]benzonitrile |
| InChI | InChI=1S/C43H45ClN8O5/c1-27-22-43(26-51(27)32-7-4-29(23-45)36(44)21-32)12-14-47(15-13-43)30-5-2-28(3-6-30)40(55)49-18-16-48(17-19-49)33-24-50(25-33)31-8-9-34-35(20-31)42(57)52(41(34)56)37-10-11-38(53)46-39(37)54/h2-9,20-21,27,33,37H,10-19,22,24-26H2,1H3,(H,46,53,54)/t27-,37?/m0/s1 |
| InChIKey | WBMJNGGUHCHFHY-YTCZSSRZSA-N |
| SMILES | C[C@H]1CC2(CCN(CC2)C3=CC=C(C=C3)C(=O)N4CCN(CC4)C5CN(C5)C6=CC7=C(C=C6)C(=O)N(C7=O)C8CCC(=O)NC8=O)CN1C9=CC(=C(C=C9)C#N)Cl |
